Terns Pharmaceuticals
TERN
TERN was delisted on the 4th of May, 2026.
34 hedge funds and large institutions have $174M invested in Terns Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 17 increasing their positions, 7 reducing their positions, and 5 closing their positions.
143% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 7
0.41% more ownership
Funds ownership: 66.14% → 66.55% (+0.41%)
6% less funds holding
Funds holding: 36 → 34 (-2)
14% less capital invested
Capital invested by funds: $204M → $174M (-$29.4M)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.71M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$725K |
| 3 |
CCM
CAAS Capital Management
New York
|
+$679K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$521K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$313K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MICM
Matthews International Capital Management
San Francisco,
California
|
-$2.04M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$927K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$223K |
| 4 |
Millennium Management
New York
|
-$181K |
| 5 |
Jane Street
New York
|
-$147K |
TERN Hedge Fund Activity: Q3 2021 in Review
34 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Terns Pharmaceuticals (TERN) for Q3 2021, worth a combined $174M — down 14% from $204M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of TERN and 3 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 17 added.
The largest buyer was BlackRock, adding an estimated $1.71M. The largest seller was Matthews International Capital Management, cutting an estimated $2.04M.
- 34 institutional investors held Terns Pharmaceuticals (TERN) as of Q3 2021, down from 36 in Q2 2021.
- Funds reported $174M of Terns Pharmaceuticals stock for Q3 2021, down 14% quarter-over-quarter.
- 3 funds opened new Terns Pharmaceuticals positions in Q3 2021 and 5 closed out, a net change of -2 holders.
- The largest Terns Pharmaceuticals buyer in Q3 2021 was BlackRock, an estimated $1.71M added.
- The largest Terns Pharmaceuticals seller in Q3 2021 was Matthews International Capital Management, an estimated $2.04M sold.
Based on aggregated 13F filings for Q3 2021.